Inclusion criteria:

          1. Written informed consent, signed and dated

          2. Subjects who are able to understand and follow instructions during the trial

          3. Age ≥18 and ≤75

          4. Subjects with newly histologically confirmed intracranial malignant glioma
             (glioblastoma WHO Grade IV) that is IDH1 wildtype (local assessment) and who are
             scheduled to receive chemo-radiotherapy with temozolomide

          5. Ability to swallow and retain oral medication

          6. Centrally obtained MGMT promoter methylation status

          7. Subjects who underwent total or partial / incomplete resection and with the
             appropriate quantity of tumour tissue releasable for eligibility and signature
             assessments

          8. Karnofsky Performance Score (KPS) > 50 %

          9. Female subjects with a childbearing potential must have a negative pregnancy test
             within one week before inclusion in the trial. Those female and male subjects admitted
             in the study must use a reliable method of contraception, for female subjects during
             the study period up until 32 days after last study treatment and for male subjects up
             until 92 days after last study administration.

             Women must be:

               -  Either of NOT childbearing potential: postmenopausal (≥ 60 years of age, or < 60
                  years of age and amenorrhoea for 12 months in the absence of chemotherapy,
                  tamoxifen, toremifene, or ovarian suppression with follicle-stimulating hormone
                  (FSH) above 40 U/L and oestradiol below 30 ng/L, or if taking tamoxifen or
                  toremifene, and age < 60 years, then FSH and oestradiol in the postmenopausal
                  range), permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral
                  salpingectomy), or otherwise incapable of pregnancy

               -  Or of childbearing potential and practicing a highly effective method of birth
                  control consistent with local regulations regarding the use of birth control
                  methods for subjects participating in clinical studies: e.g., established use of
                  oral, injected or implanted hormonal methods of contraception; placement of an
                  intrauterine device or intrauterine system; male partner sterilization (the
                  vasectomized partner should be the sole partner for that subject).

         10. A man who is sexually active and has not had a vasectomy must agree to use a barrier
             method of birth control e.g., either condom or partner with occlusive cap (diaphragm
             or cervical/vault caps).

         11. Adequate bone marrow function including: Absolute neutrophil count (ANC) ≥1,500/mm^3
             or ≥1.5 x 10^9/L; Platelets ≥ 100,000/mm3 or ≥100 x10^9/L; Haemoglobin ≥ 9 g/dL (may
             have been transfused).

         12. Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit
             of normal range (ULN), an aspartate aminotransferase (AST), level ≤ 2.5 × ULN, and an
             alanine aminotransferase (ALT) level ≤ 2.5 × ULN or, for subjects with documented
             metastatic disease to the liver, AST and ALT levels ≤ 5 × ULN. Subjects with
             documented Gilbert disease are allowed if total bilirubin ≤ 3 x ULN

         13. Adequate renal function defined by an estimated creatinine clearance ≥ 30 mL/min
             according to the Cockcroft-Gault formula

        Exclusion Criteria:

          1. Known hypersensitivity to any component of the investigational product.

          2. Any other investigational drug within the preceding 30 days. Prior, concomitant, or
             planned concomitant treatment with anti-neoplastic aim including (but not limited) to
             NovoTumor Treatment Fields (Novo TTF), bevacizumab, intratumoural or intracavitary
             anti-neoplastic therapy (e.g Gliadel wafers), or other experimental therapeutics
             intended to treat the tumour.

          3. Subjects who underwent "only biopsy" resection

          4. Anticancer therapy within 4 weeks of study entry (6 weeks for mitomycin and
             nitrosoureas)

          5. Other major surgery within the preceding 30 days

          6. Allergy, hypersensitivity or other intolerability to temozolomide and its excipients,
             patients with hypersensitivity to dacarbazine and patients with rare hereditary
             problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose
             malabsorption.

          7. Unable to undergo MRI

          8. Presenting with diffuse midline gliomas or multifocal GBM (distant from the flare or
             contralateral) or rapid progression between early post-surgery MRI and
             pre-radiotherapy MRI

          9. Uncontrolled or significant cardiovascular disease

         10. A history of uncontrolled hyperlipidaemia and/or the need for concurrent lipid
             lowering therapy

         11. Need for warfarin, phenytoin or sulphonylureas (glibenclamide, glimepiride, glipizide,
             glyburide or nateglanide)

         12. Past medical history of uncontrolled clinically significant active or chronic
             gastrointestinal disorders (for example, Crohn's disease, celiac disease, untreated
             stomach ulcers, etc) and gastro-inflammatory pathologies

         13. Uncontrolled diabetes mellitus, with glycated haemoglobin (HbA1c) levels at the
             screening visit of ≥7.5%

         14. Cardiac disease, defined specifically as either

               1. Mean resting corrected QT interval (QTc) > 470 msec (for women) and > 450 ms (for
                  men) obtained from 3 consecutive ECGs

               2. Any clinically important abnormalities in rhythm, conduction or morphology of
                  resting ECG (example, complete left bundle branch block, third degree heart
                  block)

               3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, hypokalaemia, potential for Torsades de Pointes,
                  congenital long QT syndrome, family history of long QT syndrome or unexplained
                  sudden death under 40 years of age

         15. Previous malignancies within the last three years other than ndGBM, except
             successfully treated squamous cell carcinoma of the skin, superficial bladder cancer,
             and in situ carcinoma of the cervix.